期刊
CHEMICAL & PHARMACEUTICAL BULLETIN
卷 66, 期 2, 页码 147-154出版社
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/cpb.c17-00696
关键词
oligonucleotide; bio-labile protecting group; drug delivery; prodrug
资金
- Ministry of Education, Culture, Sports, Science and Technology of Japan [17K01966]
- Grants-in-Aid for Scientific Research [17K01966] Funding Source: KAKEN
In recent years, nucleic acid-based drug therapeutics have gained considerable attention for their potential in the treatment of various diseases. However, their therapeutic value is greatly hindered by the challenge of delivering them into cells. One possible strategy to improve cellular uptake is the use of prodrug-type oligonucleotide medicine in which negatively charged phosphodiester moieties are masked by bio-labile protecting groups. In this review, we describe our recent studies related to bio-labile protecting groups for phosphodiester moieties in the development of prodrug-type oligonucleotide medicines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据